Zhejiang Anglikang Pharmaceutical Co Ltd Class A (SHE:002940) — Market Cap & Net Worth
Market Cap & Net Worth: Zhejiang Anglikang Pharmaceutical Co Ltd Class A (002940)
Zhejiang Anglikang Pharmaceutical Co Ltd Class A (SHE:002940) has a market capitalization of $823.88 Million (CN¥5.63 Billion) as of June 19, 2026. Listed on the SHE stock exchange, this China-based company holds position #9934 globally and #2655 in its home market, demonstrating a -4.48% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Zhejiang Anglikang Pharmaceutical Co Ltd Class A's stock price CN¥27.91 by its total outstanding shares 201728186 (201.73 Million). Review Zhejiang Anglikang Pharmaceutical Co Ltd debt and liabilities to assess the company's total debt and financial obligations.
Zhejiang Anglikang Pharmaceutical Co Ltd Class A Market Cap History: 2018 to 2026
Zhejiang Anglikang Pharmaceutical Co Ltd Class A's market capitalization history from 2018 to 2026. Data shows growth from $458.43 Million to $823.88 Million (9.01% CAGR).
Zhejiang Anglikang Pharmaceutical Co Ltd Class A Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Zhejiang Anglikang Pharmaceutical Co Ltd Class A's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.69x
Zhejiang Anglikang Pharmaceutical Co Ltd Class A's market cap is 0.69 times its annual revenue
Latest Price to Earnings (P/E) Ratio
7.89x
Zhejiang Anglikang Pharmaceutical Co Ltd Class A's market cap is 7.89 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $458.43 Million | $1.26 Billion | $108.70 Million | 0.37x | 4.22x |
| 2019 | $392.01 Million | $1.40 Billion | $112.27 Million | 0.28x | 3.49x |
| 2020 | $551.95 Million | $1.29 Billion | $163.72 Million | 0.43x | 3.37x |
| 2021 | $491.71 Million | $1.38 Billion | $119.84 Million | 0.36x | 4.10x |
| 2022 | $535.10 Million | $1.57 Billion | $127.30 Million | 0.34x | 4.20x |
| 2023 | $632.19 Million | $1.62 Billion | $138.37 Million | 0.39x | 4.57x |
| 2024 | $389.06 Million | $1.51 Billion | $80.33 Million | 0.26x | 4.84x |
| 2025 | $989.48 Million | $1.42 Billion | $125.44 Million | 0.69x | 7.89x |
Competitor Companies of 002940 by Market Capitalization
Companies near Zhejiang Anglikang Pharmaceutical Co Ltd Class A in the global market cap rankings as of June 19, 2026.
Key companies related to Zhejiang Anglikang Pharmaceutical Co Ltd Class A by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #513 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #560 globally with a market cap of $48.78 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #631 globally with a market cap of $43.86 Billion USD ( CN¥299.75 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #634 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #513 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #560 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $43.27 |
| #631 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $43.86 Billion | CN¥46.99 |
| #634 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €13.30 |
Zhejiang Anglikang Pharmaceutical Co Ltd Class A Historical Marketcap From 2018 to 2026
Between 2018 and today, Zhejiang Anglikang Pharmaceutical Co Ltd Class A's market cap moved from $458.43 Million to $ 823.88 Million, with a yearly change of 9.01%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥823.88 Million | -16.74% |
| 2025 | CN¥989.48 Million | +154.32% |
| 2024 | CN¥389.06 Million | -38.46% |
| 2023 | CN¥632.19 Million | +18.14% |
| 2022 | CN¥535.10 Million | +8.82% |
| 2021 | CN¥491.71 Million | -10.91% |
| 2020 | CN¥551.95 Million | +40.80% |
| 2019 | CN¥392.01 Million | -14.49% |
| 2018 | CN¥458.43 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 18th, 2026 the market cap of Zhejiang Anglikang Pharmaceutical Co Ltd Class A was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $823.88 Million USD |
| MoneyControl | $823.88 Million USD |
| MarketWatch | $823.88 Million USD |
| marketcap.company | $823.88 Million USD |
| Reuters | $823.88 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Zhejiang Anglikang Pharmaceutical Co Ltd Class A
Zhejiang AngLiKang Pharmaceutical CO.,LTD., a pharmaceutical company, engages in manufacturing APIs and pharmaceutical preparations for oral cephalosporins, cardiovascular, and kidney diseases. The company also offers products in the areas of anti-infection, cardiovascular, urinary system (nephropathy), anesthesia and pain, and anti-androgen. The company was founded in 2001 and is based in Shengz… Read more